Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.
Quick Look at Mid-day Trading | The three major stock indexes in Hong Kong all fell, with oil and coal stocks declining; all three major oil companies saw a drop of over 5%, while Tianqi Lithium Corporation surged 12% against the market trend.
Network technology stocks generally fell, with SenseTime down nearly 3%, JD.com, Netease down nearly 1%, Tencent, Alibaba slightly down; Bilibili rose by over 1%, Meituan slightly rose.
Livzon Pharmaceutical Group Inc. expects reduced performance pressure in the second half of the year | Live coverage of the earnings conference
At the earnings conference, Yang Liang, the secretary of Livzon Pharmaceutical Group Inc., responded to issues such as the year-on-year decrease in company revenue and financial data of various sector businesses. The company's CEO, Tang Yanggang, stated that the overall market size of Tocilizumab Injection is not large in China.
Another unreasonable suppression! The U.S. House of Representatives has passed the Biosecurity Act, and wuxi apptec and wuxi bio have quickly responded.
①The U.S. House of Representatives passed the draft of the Biosecurity Act (H.R.8333) with 306 votes in favor and 81 votes against. ②Wuxi Apptec, Wuxi Bio, and other companies strongly opposed it. ③This bill still needs to be voted on by the Senate and the versions passed by both houses need to be reconciled before it can be submitted to the U.S. President for signing into law.
"There are already a certain number of orders"! Can the nano-pore sequencer with a selling price of 0.4 million become a "booster" for Huada's performance?
On the 9th, BGI Group released two new nanopore sequencers, WT02 and WY01. WT02 is available for order now, and WY01 is planned to be launched in the first half of 2025. In the first half of 2024, both BGI Manufacturing and BGI Genomics experienced pressure, with high expectations on the two new nanopore sequencers from BGI Manufacturing. Chief Operating Officer of BGI Manufacturing, Jiang Hui, stated that a certain number of orders have already been generated.
BGI has launched a nanopore gene sequencing machine. Wang Jian: China needs to take a leading role in the development of life sciences.
① With the release of the nanopore gene sequencing instrument, Huada Group has become the only global institution that masters ultra-high throughput, ultra-low cost, and ultra-long read length sequencers. ② Wang Jian, the chairman of Huada Group, stated that China should take a leading role in the future development of life sciences and the bioeconomy based on big data, paving the way for global development and support.